Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 4/20 | 0.40 |
| ▸ | AURKA | O14965 | 3/20 | 0.40 |
| ▸ | MET | P08581 | 3/20 | 0.40 |
| ▸ | TEK | Q02763 | 3/20 | 0.40 |
| ▸ | LCK | P06239 | 2/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22972118 | 0.93 | POLB (0.45) | POLBMAPK1CCR1KDRAURKA | |
| SCHEMBL22972117 | 0.92 | POLB (0.44) | POLBMAPK1KDRAURKAMET | |
| SCHEMBL22972116 | 0.92 | POLB (0.45) | POLBMAPK1CCR1KDRAURKA | |
| SCHEMBL22971899 | 0.91 | POLB (0.48) | POLBMAPK1KDRAURKAMET | |
| SCHEMBL22971901 | 0.91 | POLB (0.48) | POLBMAPK1KDRAURKAMET | |
| SCHEMBL22971978 | 0.90 | POLB (0.49) | POLBMAPK1CCR1KDRAURKA | |
| SCHEMBL22971902 | 0.89 | POLB (0.45) | POLBMAPK1KDRAURKAMET | |
| SCHEMBL22972113 | 0.89 | POLB (0.41) | POLBMAPK1CCR1KDRAURKA | |
| SCHEMBL22972111 | 0.88 | ROCK2 (0.47) | POLBROCK2ROCK1 | |
| SCHEMBL22971998 | 0.87 | POLB (0.43) | POLBMAPK1CCR1KDRAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220388979-A1 | QUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B.C.I. PHARMA (BE) | 2022-12-08 | — | — | US | disclosed |
| WO-2021023888-A1 | ISOQUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B.C.I. PHARMA (BE) | 2021-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220388979-A1 | QUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ABL1, PHKB, EEF2K | POLB 2127/4885MAPK1 411/4885CCR1 4729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.